Brian Feroldi

Are investors right to bid up the stock ahead of its first NDA submission?

The royalty management company's stock dropped during the month after reporting mixed results for the second quarter.

Tension between Orexigen and its marketing partner Takeda Pharmaceuticals continues to build after reports of a recall on obesity medication Contrave surface.

Keryx shareholders received some good news from European regulators, but the share price fell anyway on an analyst downgrade. Is this a buying opportunity, or should you keep away?

Small cap biotech Keryx Pharmaceuticals' newly launched drug Auryxia looks like a clinical winner, yet the stock has been hit hard recently. Here are 5 reasons why Keryx could be a buy today.

Blue chip biotech stock Biogen has a strong pipeline full of drugs that could offer multi billion dollar opportunity. Lets take a closer look at the potential.

Medicaid focused health insurer Molina Healthcare popped today after reporting second quarter earnings. Were investors right to bid up the stock based on the news?

Shares of Genocea Biosciences fell today after the company announced the pricing terms of their secondary offering. Is the move meaningful, or just market noise?

Shares of Cempra fell today after reporting second quarter earnings. Is the move warranted, or just market noise?

These stocks hold big potential to make you a millionaire, but they are also extremely high risk. Our group of experts think you should stay away from these 3 stocks.

Biogen's stock has fallen hard recently based on slower than expected earnings growth of Tecfidera. Still, the company boasts a number of billion dollar drugs and a strong pipeline that make it an ideal choice for new biotech investors.

Jazz Pharmaceuticals is up more than 20-fold over the past five years, and strong growth in the company's narcolepsy drug Xyrem makes this Foolish contributor believe the good times will continue to roll.

Originally set out to treat the hepatitis C market, Vertex has successfully pivoted its focus to the cystic fibrosis market instead, where it looks poised for strong growth.

Shares of the contract research organization soared more than 16% today. Is the move meaningful, or just market noise?

Big biotech companies are flush with cash and are using it to reward shareholders. Here are three companies that are spending big on share buybacks.

Retirees should be looking for rock-solid businesses that offer good long-term growth prospects and shareholder friendly management teams. Here are 3 company's that fit the bill today.

The FDA has given the nod to the sale of Praluent, the first of a new class of cholesterol lowering medications, and a blockbuster opportunity for the company's.

Share of Keryx Biopharmaceuticals fell hard today on heavy volume, despite issuing a press release with good news. What was behind the stocks negative movement?

Molecular diagnostic test company Cepheid stock dropped 12% today after reporting earnings last night. Is the move justified, or just market noise?

IGI Laboratories stock surged more than 19% today after reporting second quarter results. Where results really good enough to justify such a strong move?